Clinical trial · Observational
Biobehavioral Correlates of Cancer-related Cognitive Dysfunction and Its Co-occurring Symptoms
NCT04611620CI-TRIAL-00064171completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This descriptive, cross-sectional study will evaulate and fully characterize factors associated with cognitive dysfunction in Breast Cancer (BCS) and Colorectal Cancer (CRC) survivors that have cognitive concerns, and factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anxiety | — | UNRESOLVED | — |
| Cognitive Dysfunction | — | UNRESOLVED | — |
| Depression | — | UNRESOLVED | — |
| Fatigue | — | UNRESOLVED | — |
| Pain | — | UNRESOLVED | — |
| Sleep Disturbance | — | UNRESOLVED | — |
| Survivorship | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cognitive Dysfunction | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Breast Cancer and Colorectal Cancer Survivors
- description
- The purpose of this study is to explore the factors related with cognitive concerns and other symptoms in breast and colorectal cancer survivors.
- interventionNames
- Behavioral: Cognitive Dysfunction
Primary outcomes (1)
- measure
- Subjective Cognitive Dysfunction
- timeFrame
- greater than or equal to 6 months post cancer treatment
- description
- PROMIS - Cognitive Abilities and Concerns
Secondary outcomes (5)
- measure
- Objective Cognitive Dysfunction
- timeFrame
- greater than or equal to 6 months post cancer treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: Inclusion Criteria for Breast cancer survivors: 1. Female BCS 2. ≥ 21 years of age and older 3. Ability to provide written consent and HIPAA authorization 4. ≥6 months post-adjuvant therapy and neo-adjuvant therapy for early stage (Stage I-IIIA) breast cancer. Current Aromatase Inhibitors or Tamoxifen treatment at time of enrollment is allowed. 5. Identify cognitive concerns (select yes) Inclusion Criteria for Colorectal cancer survivors: 1. Male or female CRC survivors 2. Ability to provide written consent and HIPAA authorization 3. ≥ 21 years of age and older 4. ≥6 months post-adjuvant therapy and neo-adjuvant therapy for early stage (stage I-III) CRC 5. Identify cognitive concerns (select yes) Exclusion Criteria: 1. Report metastatic breast or colorectal cancer (Stage IV) at time of consenting. 2. Unable to read and understand English to complete survey questionnaires.
References
Publications (2)
- DERIVEDGoto T, Saligan LN, Li X, Xiang L, Kwiat C, Nguyen C, Crouch A, Von Ah D. Associations of brain-derived neurotrophic factor rs6265 polymorphism and cognitive function in breast cancer survivors from a cross-sectional study. Cancer Med. 2024 Jan;13(2):e6975. doi: 10.1002/cam4.6975. PMID 38379321
- DERIVEDStorey S, Draucker C, Haunert L, Von Ah D. The Experience of Peripheral Neuropathy Symptoms in Breast Cancer Survivors With Diabetes. Cancer Nurs. 2024 Jul-Aug 01;47(4):E279-E286. doi: 10.1097/NCC.0000000000001253. Epub 2023 May 26. PMID 37232534